Tokai Pharmaceuticals Raises $35.5M in Series E Financing
Tokai Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biopharmaceutical company focused on developing new treatments for prostate cancer, raised $35.5m in a Series E financing. Backers included...
View ArticleAileron Therapeutics Secures $30M in Series E Equity Financing
Aileron Therapeutics, a Cambridge, MA-based clinical stage biopharmaceutical company, secured $30m in Series E equity financing. Backers included Apple Tree Partners, Roche Venture Fund, Novartis...
View ArticleTendyne Secures $25M in Series C Financing
Tendyne Holdings, Inc., a Roseville, MN-based clinical stage medical device company developing technologies for transcatheter mitral valve replacement, secured $25m in Series C financing. The round was...
View ArticleCerecor Closes First Tranche of $32M Series B Financing
Cerecor Inc., a Baltimore, MD-based clinical stage biopharmaceutical company developing treatments for patients suffering from nervous system disorders, closed the first tranche of a $32m Series B...
View ArticleAileron Therapeutics Secures Additional $33M in Series E Financing
Aileron Therapeutics, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company that is developing therapeutics based on its proprietary Stapled Peptide drug platform, secured $33m in an...
View ArticleVytronUS Secures $31.6M in Series B Financing
VytronUS, Inc., a Sunnyvale, CA-based medical device company developing novel technologies for the treatment of cardiac arrhythmias, secured $31.6m in Series B financing. The round was led by Apple...
View ArticleCure Forward Secures $15M in Series A Financing
Cure Forward, a New York City-based patient activation Company, secured $15m in Series A financing. The investment was made by Apple Tree Partners. The company intends to use the funds to create a...
View ArticleCorvidia Therapeutics Raises $26M in Series A Funding
Corvidia Therapeutics, a Boston, MA-based biotechnology company focused on the development of precision cardiovascular therapies, raised $26m in Series A funding. The round was co-led by Sofinnova...
View ArticleSyntimmune Raises Second $10M Tranche of $26M Series A Financing
Syntimmune, Inc., a New York-based development-stage company advancing novel treatments for IgG-mediated autoimmune diseases based on expertise in FcRn biology, raised a second $10m tranche of its $26m...
View ArticleVytronUS Raises $49M in Series C Financing
VytronUS, Inc., a Sunnyvale, Calif.-based medical device company developing novel technologies for the treatment of cardiac arrhythmias, secured $49m in Series C equity financing. Backers included...
View ArticleROX Medical Raises $40M in Funding
ROX Medical, a San Clemente, CA-based clinical-stage medical device company developing technologies for hypertension, secured $40M in Series E financing. The round was led by Novartis Venture Fund and...
View ArticleSyntimmune Raises $8M Tranche of $26M Series A Funding
Syntimmune, Inc., a Newton, MA- and New York, NY-based clinical-stage biotechnology company, raised the latest $8m tranche of its $26m Series A financing. Investors include Apple Tree Partners, Baxalta...
View ArticleSyntimmune Closes $50M in Series B Financing
Syntimmune, Inc., a NYC-based clinical-stage biotechnology company focused on FcRn biology, raised $50m in Series B financing. The round was led by Apple Tree Partners, which has committed $48 million...
View ArticleElstar Therapeutics Closes $39M Series A Financing
Elstar Therapeutics, a Cambridge, Mass.-based precision cancer immunotherapy company, closed a $39M Series A financing. Founding backer Apple Tree Partners made the investment. The funds will be used...
View ArticleStoke Therapeutics Raises $40M in Series A Financing
Stoke Therapeutics, Inc., a Bedford, MA-based new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, completed a $40m Series A financing. The...
View ArticleBraeburn Pharmaceuticals Completes $110M Mezzanine Round of Financing
Braeburn Pharmaceuticals, Inc., a Princeton, N.J.-based pharmaceutical company, completed a $110m mezzanine round of financing. The round was led by Wellington Capital Management with participation...
View ArticleCorvidia Therapeutics Secures $60M in Series B Funding
Corvidia Therapeutics Inc., a Waltham, Mass.-based clinical stage biotechnology company, closed a $60m Series B funding round. The round was led by Venrock with participation from Andera (formerly...
View ArticleAkero Therapeutics Closes $65M Series A Financing
Akero Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, completed a $65m Series A...
View ArticleStoke Therapeutics Raises $90M in Series B Financing
Stoke Therapeutics, a Bedford, Mass.-based biotechnology company, completed a $90m Series B financing. The round was led by RTW Investments with participation from founding investor Apple Tree Partners...
View ArticleAkero Therapeutics Raises $70M in Financing
Akero Therapeutics, Inc., a San Francisco, CA-based biotechnology company developing transformational treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, closed $70m...
View ArticleApple Tree Partners Promotes Four
Apple Tree Partners, a New York-based life sciences venture capital firm, has announced 4 team promotions. These include: – Sam Hall, Ph.D., has been promoted to Partner, – Aaron Kantoff has been...
View ArticleChinook Therapeutics Raises $65M in Series A Financing
Chinook Therapeutics, Inc., Vancouver, British Columbia-based precision medicines company for kidney diseases, raised $65m in Series A financing. The round was led by Versant Ventures with...
View ArticleApple Tree Partners Names Michael Ehlers as CSO and Venture Partner
Apple Tree Partners (ATP), a NYC-based life sciences fund, appointed Michael Ehlers, M.D., Ph.D., as Chief Scientific Officer and Venture Partner, and as Chief Executive Officer of portfolio company...
View ArticleLimelight Bio Raises $75M in Funding
Limelight Bio, a Philadelphia, PA- and Cambridge, MA-based multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75m in new financing. Apple Tree Partners...
View ArticleNine Square Therapeutics Launches With $50M in Series A
Nine Square Therapeutics, a San Francisco, CA-based developer of novel therapies for movement disorders, is launching with $50m in committed Series A funding. Apple Tree Partners (ATP), a life sciences...
View ArticleNereid Therapeutics Raises $50M in Series A Funding
Nereid Therapeutics, a Boston, MA-based company dedicated to discovering new disease treatments by applying research and technologies in biomolecular condensates, raised $50m in Series A funding. Apple...
View ArticleInitial Therapeutics Raises $75M in Series A Funding
Initial Therapeutics, a South San Francisco, CA-based biotechnology company, raised $75m in Series A funding. Apple Tree Partners created the company and made the initial investment. Co-founded by...
View ArticleAulos Bioscience Raises $20M in Series A Extension Financing
Aulos Bioscience, a Larkspur, CA-based immuno-oncology company, raised $20m in Series A extension funding. Apple Tree Partners (ATP) made the investment. The company intends to use the funds to advance...
View ArticleAscidian Therapeutics Raises $40M in Series A Extension Financing
Ascidian Therapeutics, a Boston, MA-based biotechnology company focused on treating human diseases by rewriting RNA, raised $40m in Series A extension funding. The funds were committed by Apple Tree...
View ArticleDeep Apple Therapeutics Raises $52M in Series A Funding
Deep Apple Therapeutics, a San Francisco, CA-based company that discovers novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries, raised...
View Article
